Great Basin Scientific Establishes Health Systems Executive Sales Team

SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced the establishment of Great Basin Health Systems, a sales team formed to expand the Company’s sales efforts into previously untapped provider groups and networks searching for vendor partners to help them achieve improved patient care and lower patient costs. Heather Schram and Tamara Stojanovski, seasoned sales executives, will lead Great Basin Health Systems’ efforts.

“We are excited to welcome Heather and Tamara—two extremely accomplished and respected sales executives—to Great Basin”

“Hospitals greatly need our versatile, cost effective and easy-to-use molecular diagnostics solution, however too many are currently constrained from adopting Great Basin by purchasing systems that simply are not yet aware of Great Basin and the exceptional advantages our system can offer their hospitals,” said Sandra Nielsen, senior vice president of sales, marketing and human resources. “By engaging directly with these networks, we see a remarkable opportunity to reach more hospitals faster, which we believe will accelerate growth in our customer base and help hospitals improve patient outcomes while providing a valuable cost-savings for the hospital and hospital network. We’re thrilled to be able to introduce our system to a larger segment of the marketplace.”

In this new role, both Ms. Schram and Ms. Stojanovski will work with Group Purchasing Organizations (GPO), Integrated Delivery Networks (IDN) and Regional Purchasing Coalitions (RPC) as a vendor partner that can help achieve quality outcomes, while reducing total cost of care. Great Basin Health Systems will provide individual hospitals greater access to Great Basin’s technology through contracting at the group level, and creating strategies for long-term partnerships with groups and networks focused on achieving mutual objectives.

“We are excited to welcome Heather and Tamara—two extremely accomplished and respected sales executives—to Great Basin,” said Mike Blitz, vice president of U.S. Sales for Great Basin. “They represent the first phase of the Company’s aggressive Sales expansion objectives for the next 18 months and we look forward to this team introducing untapped markets to our unique and compelling business model that places our analyzer at no cost, allowing a hospital lab to adopt molecular diagnostic testing without any capital expenditure. That model, coupled with our expanding menu of tests and panels makes Great Basin a peerless molecular diagnostic solution to partner with for a variety of hospital groups and networks.”

Ms. Schram joins Great Basin from Acelity, a wound care and regenerative medicine company based in Texas, where she served as a national account director responsible for developing relationships to establish the company as a strong strategic partner for hospitals and healthcare systems. She also worked to maximize revenue and profitability through development of specialized programs with strategic customers including IDNs, GPOs, and RPCs. Prior to her work with Acelity, Ms. Schram served in a number of sales leadership positions, including director of national accounts at Meridian Bioscience, Inc. in Ohio, and territory manager at California-based Sage Products/BioSafety Systems. Ms. Schram earned a B.S. in business administration at University of Northern Colorado, completed a program on negotiation and leadership at Harvard Law School and has been recognized with numerous sales performance awards throughout her career.

Ms. Stojanovski comes to Great Basin having previously served as director of corporate accounts at Acelity, where she was responsible for developing strategies, tactics and contracts focused on accelerating product adoption and revenue growth in key IDNs. Through her tenure at Acelity, Ms. Stojanovski successfully delivered an impactful value message to appropriate stakeholders including supply chain, VAT directors, chief nursing officers, surgeons and GPOs. Ms. Stojanovski previously served as a regional director at Premier Healthcare Alliance in North Carolina, and as regional sales manager of the southwest region at Meridian Bioscience. Notably, Ms. Stojanovski obtained the first GPO contract for Meridian Bioscience for its then-new molecular platform. She earned her B.S. in advertising from University of Illinois, Champaign-Urbana, Ill., and received a full fellowship from the J.L. Kellogg Graduate School of Management, Northwestern in the department of marketing’s Ph.D. program.

Ms. Schram and Ms. Stojanovski will report to Mike Blitz.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, statements regarding potential customer growth through the Great Basin Health Systems sales team and other similar statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2015 and the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.